Related Experiment Video
Updated: May 26, 2025
Following Cell-fate in E. coli After Infection by Phage Lambda
Published on: October 14, 2011
A new bacteriophage infecting Staphylococcus epidermidis with potential for removing biofilms by combination with
Ana Catarina Duarte1,2, Lucía Fernández1,2, Ana Rodríguez1,2
1Instituto de Productos Lácteos de Asturias (IPLA-CSIC), Oviedo, Asturias, Spain.
Abstract:
Staphylococcus epidermidis is the cause of serious skin and prosthetic joint infections despite being a common inhabitant of human body surfaces. However, both the rise in antibiotic resistance in this species and its ability to form biofilms are increasingly limiting the available therapeutic options against these illnesses. In this landscape, phage therapy stands out as an interesting alternative to antibiotics. In the present study, we report the isolation and characterization of a novel virulent phage infecting S. epidermidis (Staphylococcus phage IPLA-AICAT), which belongs to the Herelleviridae family. The estimated genome size of this virus is 139,941 bp, and sequence analysis demonstrated the absence of antibiotic resistance genes and virulence factors. This phage infects a high proportion (79%) of clinically relevant S. epidermidis strains and exhibits antibiofilm activity. Moreover, a combination of this phage with other antimicrobials, i.e., vancomycin and the lytic protein CHAPSH3b, further improved the reduction in surface-attached bacteria. Notably, the combination of Staphylococcus phage IPLA-AICAT (109 PFU/mL) and CHAPSH3b (8 µM), originally designed to target Staphylococcus aureus, was able to reduce the number of viable cells by 3.06 log units in 5-h-old biofilms. In 24-h-old biofilms, the reduction was also significant after 6 h of treatment (2.06 log units) and 24 h of treatment (2.52 log units). These results confirm our previous data regarding the potential of phage-lysin mixtures against staphylococcal biofilms.IMPORTANCEStaphylococcus epidermidis is one of the main causes to device-associated infections mostly due to its ability to form stable biofilms attached to human tissues. Besides the inherent antimicrobial tolerance of biofilms, this microorganism is also increasingly becoming resistant to standard-of-care antibiotics. To fight against this problem, phage therapy is a viable option to complement the available antibiotics in the treatment of recalcitrant infections. This work describes a new phage infecting S. epidermidis clinical strains that is a member of the Herelleviridae family and the combination with other antimicrobials to further improve the reduction of biofilms. Together with the significant progress achieved in the development of diagnostic tools, phages and their derived proteins will bring us much closer to a therapeutic landscape in which we are not so heavily reliant on antibiotics to combat bacterial pathogens.
Insights
A novel bacteriophage, Staphylococcus phage IPLA-AICAT, effectively targets antibiotic-resistant Staphylococcus epidermidis biofilms. Combining this phage with antimicrobials like vancomycin or CHAPSH3b enhances biofilm reduction, offering a promising alternative to traditional antibiotics.
Area of Science:
- Microbiology
- Virology
- Biotechnology
Background:
- Staphylococcus epidermidis causes significant device-associated infections, exacerbated by antibiotic resistance and biofilm formation.
- Limited therapeutic options exist for S. epidermidis infections due to these challenges.
- Phage therapy presents a potential alternative to conventional antibiotics.
Purpose of the Study:
- To isolate and characterize a novel virulent bacteriophage targeting S. epidermidis.
- To evaluate the antibiofilm efficacy of the isolated phage, individually and in combination with other antimicrobials.
- To assess the phage's potential as a therapeutic agent against S. epidermidis biofilms.
Main Methods:
- Isolation and characterization of a novel virulent phage, Staphylococcus phage IPLA-AICAT, from the Herelleviridae family.
- Genome sequencing to identify absence of antibiotic resistance genes and virulence factors.
- In vitro testing of phage efficacy against S. epidermidis biofilms, including combinations with vancomycin and CHAPSH3b.
Main Results:
- The novel phage, Staphylococcus phage IPLA-AICAT, infects 79% of clinical S. epidermidis strains and shows antibiofilm activity.
- Combinations of the phage with vancomycin or CHAPSH3b significantly enhanced biofilm reduction.
- Specific phage-lysin combinations demonstrated substantial reduction in viable cells within S. epidermidis biofilms.
Conclusions:
- Staphylococcus phage IPLA-AICAT is a promising candidate for phage therapy against S. epidermidis infections.
- Phage-antimicrobial combinations offer a synergistic approach to combat challenging staphylococcal biofilms.
- Phage therapy and derived proteins represent a viable strategy to reduce reliance on antibiotics for treating bacterial pathogens.
More Related Videos
Related Concept Videos
01:30Lytic Cycle of Bacteriophages
00:43Lysogenic Cycle of Bacteriophages
00:50What are Viruses?
02:53CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...